Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 214

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model

Open access
Capell, Brian C., Olive, Michelle, Erdos, Michael R., Cao, Kan, Faddah, Dina A., Tavarez, Urraca L., Conneely, Karen N., Qu, Xuan, San, Hong, Ganesh, Santhi K., Chen, Xiaoyan, Avallone, Hedwig, Kolodgie, Frank D., Virmani, Renu, Nabel, Elizabeth G., Collins, Francis S.·2008·Proceedings of the National Academy of Sciences

Abstract

Hutchinson-Gilford progeria syndrome (HGPS) is the most dramatic form of human premature aging. Death occurs at a mean age of 13 years, usually from heart attack or stroke. Almost all cases of HGPS are caused by a de novo point mutation in the lamin A ( LMNA ) gene that results in production of a mutant lamin A protein termed progerin. This protein is permanently modified by a lipid farnesyl group, and acts as a dominant negative, disrupting nuclear structure. Treatment with farnesyltransferase inhibitors (FTIs) has been shown to prevent and even reverse this nuclear abnormality in cultured HGPS fibroblasts. We have previously created a mouse model of HGPS that shows progressive loss of vascular smooth muscle cells in the media of the large arteries, in a pattern that is strikingly similar to the cardiovascular disease seen in patients with HGPS. Here we show that the dose-dependent administration of the FTI tipifarnib (R115777, Zarnestra) to this HGPS mouse model can significantly prevent both the onset of the cardiovascular phenotype as well as the late progression of existing cardiovascular disease. These observations provide encouraging evidence for the current clinical trial of FTIs for this rare and devastating disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0807840105

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 214

Metadata

Authors
Capell, B. C., Olive, M., Erdos, M. R., Cao, K., Faddah, D. A., Tavarez, U. L., Conneely, K. N., Qu, X., San, H., Ganesh, S. K., Chen, X., Avallone, H., Kolodgie, F. D., Virmani, R., Nabel, E. G., & Collins, F. S.
Venue
Proceedings of the National Academy of Sciences
Published
2008-10-14
Volume
105
Issue
41
Pages
15902-15907
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2156516895
Cited by
214
References
1
FWCI
6.70
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. https://app.cochat.ai/papers/10.1073/pnas.0807840105
The paper
Capell, B. C., Olive, M., Erdos, M. R., Cao, K., Faddah, D. A., Tavarez, U. L., Conneely, K. N., Qu, X., San, H., Ganesh, S. K., Chen, X., Avallone, H., Kolodgie, F. D., Virmani, R., Nabel, E. G., & Collins, F. S. (2008). A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0807840105

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.